What are the various Epidermolysis Bullosa Therapeutics available in market today?

 

  Epidermolysis Bullosa, otherwise known as EBT, is a rare group of hereditary disorders where the epidermis forms severe blisters after slight physical friction or injury and becomes extremely fragile. Hence, for the delay in the correct diagnosis and the subsequent unawareness of proper treatment options, many governments, and other non-governmental organizations have been conducting different awareness programs over the years. The treatments involved in the Epidermolysis Bullosa Therapeutic System are relatively simple and easy to administer at home.

  Epidermolysis Bullosa is an uncommon group of hereditary disorders where the epidermis becomes extremely fragile and forms severe blistering and painful blisters even after a very minor injury or mild friction. This condition is characterized by severe inflammation which causes the dermis layer of the skin to break down, exposing the underlying basement membrane. Epidermolysis also causes fibrous cords that form within the blister, and it can spread to other areas of the body. One promising approach for treating this condition has been developed using novel genetic and enzyme genetic technologies. Genetically engineered mice have been generated with a defective gene that causes EB (eb). Using mouse models, scientists have been able to generate genetically identical disease-free animals that are capable of healing themselves when exposed to the common allergens that cause the condition.

  The Epidermolysis Bullosa therapy is made up of pharmaceutical-grade pharmaceuticals such as aminexin, ebogen, ebizon, and atenolol. Since the initiation of the phase ii trial of ebb-101, there have been several major milestones achieved in the manufacture of the EBTherapeutics. One of the milestones is the successful completion of this early on-stage drug. The other milestone is the successful completion of the second phase of the therapy. The mice thus generated have shown the potential to provide a useful platform for developing new medications that can target the defective genes, stopping the vicious cycle that leads to the manifestation of the condition. Several promising EB Therapeutics products are now in pre-clinical development and may soon find a place.